The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Iberdomide + dexamethasone in R/R multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, presents the results of a study evaluating iberdomide, a cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone in patients with triple-class refractory multiple myeloma or in patients who have been exposed to an anti-BCMA agent (NCT02773030). The overall response rate (ORR) reached 30% in both patient groups and the median progression-free survival (PFS) was three months. Dr Popat explains that in contrast to pomalidomide and lenalidomide, iberdomide is associated with significantly lower rates of non-hematological toxicity. In the future, iberdomide will be evaluated in combination with proteasome inhibitors, monoclonal antibodies and as a maintenance strategy post-transplantation. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
